Study of Antifungal Activity of Experimental Soft Dosage Form Based on the Hydrazone Derivative of Getarylamide 4-phenyl-2-hydroxy-4-oxo-2-butenoic acid
Open Access
- 26 December 2022
- journal article
- research article
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 11 (4) , 43-47
Abstract
Introduction. Recently, there has been a significant increase in fungal infections. The most common is vulvovaginal candidiasis, affecting millions of women worldwide. Resistance is formed to existing antifungal drugs, and they are not devoid of side effects. Previously, we have shown high antimicrobial activity of derivatives of 4-R-2-hydroxy-4-oxo-2-butenic acids. The creation of soft dosage forms based on them and the study of antifungal action is promising.Aim. To develop experimental soft dosage forms based on one of the most active derivatives of 4-R-2-hydroxy-4-oxo-2-butenic acids and to evaluate the effect of the ointment composition of the ointment composition on the severity of antifungal action.Materials and methods. As a pharmacologically active component, a hydrazone derivative of 4-phenyl-2-hydroxy-4-oxo-2-butenoic acid synthesized by us was used, which has pronounced antifungal activity. 8 experimental soft dosage forms based on hydrophobic and hydrophilic character have been developed. The active substance in a concentration of 1 % was introduced by standard technological methods according to the rules for the manufacture of dermatological ointments. To determine the antifungal activity of the ointments obtained, a three-nesting variant of the agar diffusion method was used. Comparison preparations are 2 % cream "Pimafucin" and 1 % cream "Clotrimazole".Results and discussion. All the studied experimental soft dosage forms showed antifungal effects of varying degrees of severity. The greatest pharmacological effect was found in ointment compositions based on hydrophilic components of sodium-carboxymethylcellulose and polyethylene oxides. Their antifungal effect is comparable or exceeds the effect of comparison drugs.Conclusion. 8 experimental soft dosage forms based on a derivative of 4-phenyl-2-hydroxy-4-oxo-2-butenic acid have been developed. Their antifungal activity has been studied. Two most active samples of experimental ointments were selected for further in-depth study.Keywords
This publication has 10 references indexed in Scilit:
- Effects of Boric Acid Gel on Vaginal Candida albicans Infections and the Local Immune System in MiceFrontiers in Immunology, 2022
- Prevalence and Risk Factors of Vulvovaginal Candidosis during Pregnancy: A ReviewInfectious Diseases in Obstetrics and Gynecology, 2022
- Lab-Based Retrospective 10-Year Analysis Shows Seasonal Variation of Vaginal Candida Infection Rates in BelgiumJournal of Clinical Medicine, 2022
- Evaluation of overtime phenotypic variation of yeasts in chronic vulvovaginal candidosis casesMedical Mycology, 2021
- Sodium bicarbonate gels: a new promising strategy for the treatment of vulvovaginal candidosisEuropean Journal of Pharmaceutical Sciences, 2021
- Vulvovaginal Candidosis: Current Concepts, Challenges and PerspectivesJournal of Fungi, 2020
- Antifungal activity of new derivatives of 4-(het)aryl-2,4-dioxobutanoic acidsReviews on Clinical Pharmacology and Drug Therapy, 2020
- Recurrent Vulvovaginal Candidosis and Cluster Analysis of Clinical Signs and Symptoms: A Laboratory-Based InvestigationJournal of Fungi, 2020
- Synthesis and Antimicrobial Activity of Methyl (2Z)-4-Aryl-2-{4-[(4,6-dimethylpyrimidin-2-yl)sulfamoyl]phenylamino}-4-oxobut-2-enoates and Their Silver SaltsRussian Journal of General Chemistry, 2020
- Synthesis and Biological Activity of 4-Aryl-N-(5,6-R-benzo[d]thiazol-2-yl)- 2-hydroxy-4-oxobut-2-enamidesRussian Journal of General Chemistry, 2018